Moskovitz B, Nitecki S, Richter Levin D
Urol Int. 1987;42(1):49-52. doi: 10.1159/000281849.
Adenocarcinoma of the prostate constitutes 18% of all cancers in men, and is a major cause of neoplastic death second only to carcinoma of lungs and large bowel. In spite of the high incidence of the disease, there is still disagreement as to the right treatment. In our study we reviewed 101 patients in stages T0b, T1 + T2, T3 (N0M0) who were treated by nonradical prostatectomy and no other treatment. The follow-up of these patients was 58 months. The actuarial 5- and 10-year survival according to stage was respectively: 91.30 and 64.62% in stage T0b; 60.61 and 34.11% in stage T1 + T2, and 41.67% in stage T3. Survival rates resembled those quoted in the literature. Our results justify a less aggressive approach to carcinoma of the prostate.
前列腺腺癌占男性所有癌症的18%，是仅次于肺癌和大肠癌的肿瘤性死亡的主要原因。尽管该疾病发病率很高，但对于正确的治疗方法仍存在分歧。在我们的研究中，我们回顾了101例处于T0b、T1 + T2、T3（N0M0）期的患者，这些患者接受了非根治性前列腺切除术且未接受其他治疗。对这些患者的随访时间为58个月。根据分期，精算的5年和10年生存率分别为：T0b期为91.30%和64.62%；T1 + T2期为60.61%和34.11%，T3期为41.67%。生存率与文献中引用的相似。我们的结果证明对前列腺癌采取较不积极的治疗方法是合理的。
